SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors discuss the upcoming CHMP opinion on Blarcamesine for Alzheimer's treatment, with community members highlighting the oral explanation and potential for approval. The conversation centers on whether the drug will be on the agenda and the potential for partnerships following a positive decision. Some are also discussing the possibility of a short squeeze, while others express concerns about market manipulation.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Fueling recent volatility, Galecto (GLTO) has seen significant swings, prompting discussions around acquisition news and financing. Community members are weighing short squeeze potential against concerns of a possible dilution machine. Traders are actively watching GLTO, MOVE, and other low float stocks for similar patterns.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is trending following the announcement that the company is exploring strategic alternatives, including a potential sale or merger, to maximize shareholder value, leading to speculation about a potential acquisition. Community members are actively discussing potential offers and the company's underlying value, while some express skepticism, pointing to past performance. The stock's low float and existing patents contribute to volatile trading, with many anticipating further price movement.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya is trending as investors discuss the potential impact of recent earnings beats, guidance raises, and high short interest, with some anticipating a significant short squeeze. The community is focused on the company's AI-driven credit analysis and potential for growth amid changing macroeconomic conditions. Some are concerned about the broader fintech sector and are keeping an eye on upcoming earnings.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending as investors express frustration with the stock's performance and CEO Michael Castagna, especially following disappointing trial results for their inhaled clofazimine (MNKD-101) study; the community is actively discussing the need for new leadership and questioning the company's strategic direction. Despite positive developments with Tyvaso DPI and potential future revenue streams, concerns linger about Mannkind's ability to generate value and achieve sustained growth, prompting calls for strategic changes, including a potential sale or merger.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its growth potential, highlighted by a recent analyst buy rating and strong cash position, despite some community concerns around weekly options activity.  Enthusiasm is fueled by speculation about partnerships with tech giants like Amazon and Google, while others point to high short interest as a catalyst for a potential squeeze. Community members are actively debating the company's valuation and future prospects in the competitive AI landscape.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics ($GALT) is trending as investors digest data presented at a recent conference, with community members highlighting the drug's potential impact on liver fibrosis and variceal development. Discussions revolve around the significance of biomarker data and potential synergies with GLP-1 therapies. The community speculates on potential buyout scenarios and the timing of key events, such as presentations at an upcoming liver meeting and a meeting with the FDA.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a significant slump despite Q3 earnings exceeding expectations, attributed to a Q4 revenue outlook falling short of estimates. Community discussions revolve around the potential gap at a specific price point and the impact of AI on the company's growth. Some investors express distrust in Israeli tech companies, while others view the dip as an overreaction and a buying opportunity.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global ($VG) is trending amid discussions about its Q3 2025 earnings, with community members dissecting revenue, EBITDA guidance, and long-term contracts, including a recent agreement with a Spanish company.  Despite some debate, many see a valuation gap compared to competitors and are closely watching developments with LNG exports and potential catalysts for future growth.  Ongoing arbitration cases and their potential impact on the company's financial outlook remain a key concern.

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

COGT is trending due to positive Phase 3 PEAK data for its GIST drug, bezuclastinib, which showed significant improvement compared to existing treatments. The community is excited about the potential for a new standard of care and analysts are raising price targets, with some speculating about a potential acquisition given the strong institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brokers Offer Predictions for Peabody Energy FY2025 Earnings

Peabody Energy Corporation (NYSE:BTU - Free Report) - Investment analysts at B. Riley reduced their FY2025 earnings per share (EPS) estimates for shares of Peabody Energy in a note issued to...

FY2026 EPS Estimates for Peabody Energy Reduced by B. Riley

Peabody Energy Corporation (NYSE:BTU - Free Report) - Investment analysts at B. Riley lowered their FY2026 earnings per share estimates for shares of Peabody Energy in a research report issued on...

Peabody Energy (BTU) Reports Q3 Loss, Beats Revenue Estimates

Peabody Energy (BTU) delivered earnings and revenue surprises of -205.26% and +4.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Peabody Reports Results For Quarter Ended September 30, 2025

Peabody Reports Results For Quarter Ended September 30, 2025 Peabody Reports Results For Quarter Ended September 30, 2025 PR Newswire ST. LOUIS, Oct. 30, 2025 Adjusted EBITDA Rises from Q2 On Higher...

Peabody Board Declares Dividend on Common Stock

Peabody Board Declares Dividend on Common Stock Peabody Board Declares Dividend on Common Stock PR Newswire ST. LOUIS, Oct. 30, 2025 ST. LOUIS, Oct. 30, 2025 /PRNewswire/ -- Peabody (NYSE: BTU...

Ramaco Resources (METC) Reports Q3 Loss, Lags Revenue Estimates

Ramaco Resources (METC) delivered earnings and revenue surprises of +24.24% and -3.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Peabody Energy (BTU) Q3 Earnings Expected to Decline

Peabody Energy (BTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Peabody to Announce Results for the Quarter Ended Sept. 30, 2025

Peabody to Announce Results for the Quarter Ended Sept. 30, 2025 Peabody to Announce Results for the Quarter Ended Sept. 30, 2025 PR Newswire ST. LOUIS, Oct. 21, 2025 ST. LOUIS, Oct. 21, 2025...

Peabody Energy shares shot up 2% on Tuesday morning after the company terminated its $3.8 billion deal with Anglo American due to a material adverse change (MAC) relating to Anglo's steelmaking coal assets.Peabody said the decision to terminate the transaction comes nearly five months after an ignition event occurred at Anglo's Moranbah North Mine. “The exact cause of the event remains unknown, with no definitive timeline to resuming sustainable longwall production,” the company added.Retail sentiment on Peabody improved to ‘neutral’ from ‘bearish’ territory, with chatter at ‘low’ levels, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:800/92;" src="https://news.stocktwits-cdn.com/BTU_sentiment_png_57fb127102.webp" alt="BTU sentiment.png" width="800" height="92"><figcaption>BTU sentiment and message volume August 19, 2025, as of 9 am ET | Source: Stocktwits</figcaption></figure>Last year, the U.S. mining company reached an agreement to acquire mines located in Queensland’s Bowen Basin, which is known to be a leading global hub for coking coal. In March, Moranbah North mine was closed due to high gas levels, which resulted in Peabody stating that this would allow it to break or renegotiate a deal if an adverse event occurred."The two companies did not reach a revised agreement to cure the MAC that compensated Peabody for the material and long-term impacts of the MAC on the most significant mine in the planned acquisition," said Peabody President and CEO Jim Grech.Peabody said before the March 31 event, the acquisition had been scheduled to close in April 2025. Anglo estimates $45 million per month of holding costs at Moranbah North.Anglo American CEO Duncan Wanblad said&nbsp;that the company was confident that the event at Moranbah North did not constitute a MAC under the sale agreements with Peabody. “Our view is supported by the lack of damage to the mine and equipment, as well as the substantial progress made with the regulator, our employees and the unions, and other stakeholders as part of the regulatory process towards a safe restart of the mine,” he added.Wanblad said the company was “very disappointed that Peabody has decided not to complete the transaction.” “Despite our strongly held view, we believe that it would have been better for all parties to avoid a legal dispute,” Wanbald said, adding that following Peabody’s decision not to proceed with the transaction, Anglo continues to focus on the safe restart of Moranbah North.A bullish user on Stocktwits noted that Peabody shares could go back $29 a share following the termination.<stembedurl>https://stocktwits.com/russellkbrett/message/625746066</stembedurl><a href="https://stocktwits.com/symbol/BTU">Peabody stock</a> declined over 18% so far this year and has lost 24% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/the-first-home-improvement-retailer-to-report-results-this-week-misses-q2-earnings/chsg17uRdgo">The First Home Improvement Retailer To Report Results This Week Misses Q2 Earnings, Retail Investors Call Out ‘High Prices’</a>

Peabody Energy building, in St. Louis, Missouri on NOVEMBER 02, 2012. (Photo By Raymond Boyd/Michael Ochs Archives/Getty Images)

Peabody Stock Surged Today Following The Termination Of This Deal – More Details Inside

Peabody said the decision to terminate the transaction comes nearly five months after an ignition event occurred at Anglo's Moranbah North Mine.

Equity

Peabody Energy (BTU) Reports Q2 Loss, Lags Revenue Estimates

Peabody Energy (BTU) delivered earnings and revenue surprises of -50.00% and -5.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Peabody Energy Corp. engages in the business of coal mining. It operates through the following business segments: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal, and Corporate and Other. The Seaborne Thermal segment consist of mines in New South Wales, Australia. The Seaborne Metallurgical segment includes mines in Queensland, Australia, one in New South Wales, Australia and one in Alabama, USA. The Powder River Basin segment focuses on mines in Wyoming. The Other U.S. Thermal segment reflects on the mining, preparation and sale of thermal coal, sold primarily to electric utilities in the U.S. under long-term contracts, with a relatively small portion sold as international exports as conditions warrant. The Corporate and Other segment involves administrative expenses, results from equity method investments, trading and brokerage activities, minimum charges on certain transportation-related contracts, the closure of inactive mining sites, the impact of foreign currency remeasurement and certain commercial matters. The company was founded by Francis S. Peabody in 1883 and is headquartered in St. Louis, MO.

Peabody Energy Corp. - Ordinary Shares New

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.20	--	--	N/A
Q3 '25	-$0.01	-$0.57	-8467.56%	MISSED
Q2 '25	-$0.00	-$0.22	-11022.35%	MISSED
Q1 '25	$0.05	$0.27	490.16%	BEAT
Q4 '24	$0.42	$0.25	-41.11%	MISSED

BTU
Peabody Energy Corp. - Ordinary Shares New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest BTU News

BTUPeabody Energy Corp. - Ordinary Shares New